Orforglipron: uses, evidence, cost and safety
Orforglipron is an oral, small-molecule (non-peptide) GLP-1 receptor agonist. Unlike injectable agonists and oral semaglutide, it is designed to be taken as a pill without strict food-and-water timing. Its regulatory status is changing quickly; confirm the current FDA position and any brand availability before treating this as a settled option.
What Orforglipron is
Orforglipron is a oral non-peptide glp-1 receptor agonist. It is marketed as Foundayo (as referenced in market reporting). Orforglipron is an oral, small-molecule (non-peptide) GLP-1 receptor agonist. Unlike injectable agonists and oral semaglutide, it is designed to be taken as a pill without strict food-and-water timing. Its regulatory status is changing quickly; confirm the current FDA position and any brand availability before treating this as a settled option.
Regulatory status
Approval status is evolving — verify current FDA status before relying on this page.
How does it work?
Activates the GLP-1 receptor via a small molecule that can be manufactured as a conventional oral tablet, potentially lowering production cost versus peptide drugs.
Clinical evidence
Phase 3 readouts for weight management and type 2 diabetes have been reported; consult the current FDA label and primary trial publications for exact figures, which are outside our verified cutoff.
| Trial | Arm | Result | Duration | Comparator | Source |
|---|---|---|---|---|---|
| SURMOUNT-1 | Tirzepatide 15 mg | −20.9% | 72 weeks | Placebo −3.1% | NEJM 2022 (Jastreboff et al.) |
| SURMOUNT-1 | Tirzepatide 10 mg | −19.5% | 72 weeks | NEJM 2022 | |
| SURMOUNT-1 | Tirzepatide 5 mg | −15.0% | 72 weeks | NEJM 2022 | |
| SURMOUNT-5 | Tirzepatide (max tolerated) | −20.2% | 72 weeks | vs semaglutide −13.7% | NEJM 2025 (Aronne et al.) |
| STEP 1 | Semaglutide 2.4 mg | −14.9% | 68 weeks | Placebo −2.4% | NEJM 2021 (Wilding et al.) |
| STEP 8 | Semaglutide 2.4 mg | −15.8% | 68 weeks | vs liraglutide 3.0 mg −6.4% | JAMA 2022 (Rubino et al.) |
| SCALE | Liraglutide 3.0 mg | −8.0% | 56 weeks | Placebo −2.6% | NEJM 2015 |
| SELECT | Semaglutide 2.4 mg | 20% MACE reduction | ~40 months | Cardiovascular outcomes | NEJM 2023 |
Dosing and titration
See the FDA label for the approved dose schedule.
Common and serious side effects
Gastrointestinal effects consistent with the GLP-1 class were reported in trials.
Warnings and contraindications
As an oral GLP-1 agonist, class warnings apply. Confirm current labeling; do not present availability as settled.
Frequently asked questions
Is Orforglipron FDA-approved?
Approval status is evolving — verify current FDA status before relying on this page.
How does Orforglipron work?
Activates the GLP-1 receptor via a small molecule that can be manufactured as a conventional oral tablet, potentially lowering production cost versus peptide drugs.
What are the most common side effects of Orforglipron?
Gastrointestinal effects consistent with the GLP-1 class were reported in trials.
Who should not take Orforglipron?
As an oral GLP-1 agonist, class warnings apply. Confirm current labeling; do not present availability as settled.
Sources
- U.S. Food and Drug Administration — prescribing information and drug labels for Foundayo (as referenced in market reporting).
- Pivotal randomized controlled trials as cited in the evidence section (SURMOUNT, SURPASS, STEP, SUSTAIN, SCALE as applicable).
- CMS National Plan & Provider Enumeration System — clinician verification for reviewed providers.
- ClinicalTrials.gov — trial registrations for investigational agents.